These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26303081)

  • 21. LncRNA BCAR4 wires up signaling transduction in breast cancer.
    Xing Z; Park PK; Lin C; Yang L
    RNA Biol; 2015; 12(7):681-9. PubMed ID: 26016563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-coding RNAs as potential therapeutic targets in breast cancer.
    Tomar D; Yadav AS; Kumar D; Bhadauriya G; Kundu GC
    Biochim Biophys Acta Gene Regul Mech; 2020 Apr; 1863(4):194378. PubMed ID: 31048026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Nuclear Receptors with PROTAC degraders.
    Flanagan JJ; Neklesa TK
    Mol Cell Endocrinol; 2019 Aug; 493():110452. PubMed ID: 31125586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.
    Li X; Wu Y; Liu A; Tang X
    Tumour Biol; 2016 Nov; 37(11):14733-14743. PubMed ID: 27629141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ubiquitin-like protein modifications in prostate and breast cancer.
    Wu F; Mo YY
    Front Biosci; 2007 Jan; 12():700-11. PubMed ID: 17127330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer.
    Capper CP; Rae JM; Auchus RJ
    Horm Cancer; 2016 Jun; 7(3):149-64. PubMed ID: 26969590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolving understanding of growth regulation in human breast cancer: interactions of the steroid and peptide growth regulatory pathways.
    Wilson CA; Slamon DJ
    J Natl Cancer Inst; 2005 Sep; 97(17):1238-9. PubMed ID: 16145037
    [No Abstract]   [Full Text] [Related]  

  • 28. ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.
    Wrobel K; Zhao YC; Kulkoyluoglu E; Chen KL; Hieronymi K; Holloway J; Li S; Ray T; Ray PS; Landesman Y; Lipka AE; Smith RL; Madak-Erdogan Z
    Mol Endocrinol; 2016 Oct; 30(10):1029-1045. PubMed ID: 27533791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Noncoding RNAs in breast cancer.
    Lo PK; Wolfson B; Zhou X; Duru N; Gernapudi R; Zhou Q
    Brief Funct Genomics; 2016 May; 15(3):200-21. PubMed ID: 26685283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long non-coding RNAs related to androgen receptor function in prostate cancer: Advances in studies].
    Wang M; Ying J; Zhang M; Liang CZ
    Zhonghua Nan Ke Xue; 2019 Aug; 25(8):739-743. PubMed ID: 32227719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer.
    Shi Q; Li Y; Li S; Jin L; Lai H; Wu Y; Cai Z; Zhu M; Li Q; Li Y; Wang J; Liu Y; Wu Z; Song E; Liu Q
    Nat Commun; 2020 Nov; 11(1):5513. PubMed ID: 33139730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer.
    Xu S; Wang P; Zhang J; Wu H; Sui S; Zhang J; Wang Q; Qiao K; Yang W; Xu H; Pang D
    Mol Cancer; 2019 Apr; 18(1):89. PubMed ID: 30999914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers.
    Barwal TS; Sharma U; Bazala S; Singh I; Jain M; Prakash H; Shekhar S; Sandberg EN; Bishayee A; Jain A
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long non-coding RNA FOXD3 antisense RNA 1 augments anti-estrogen resistance in breast cancer cells through the microRNA-363/ trefoil factor 1/ phosphatidylinositol 3-kinase/protein kinase B axis.
    Ren L; Zhou H; Lei L; Zhang Y; Cai H; Wang X
    Bioengineered; 2021 Dec; 12(1):5266-5278. PubMed ID: 34424807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer.
    Pecero ML; Salvador-Bofill J; Molina-Pinelo S
    Cell Oncol (Dordr); 2019 Feb; 42(1):1-12. PubMed ID: 30361825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK.
    Si X; Zang R; Zhang E; Liu Y; Shi X; Zhang E; Shao L; Li A; Yang N; Han X; Pan B; Zhang Z; Sun L; Sun Y
    Oncotarget; 2016 Dec; 7(49):81452-81462. PubMed ID: 27845892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nuclear hormone receptor co-repressors.
    Baniahmad A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):89-97. PubMed ID: 15860250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR‑125a‑5p.
    Liu Y; Li M; Yu H; Piao H
    Int J Mol Med; 2020 Feb; 45(2):497-509. PubMed ID: 31894257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1.
    Wang R; Zhang T; Yang Z; Jiang C; Seng J
    J Cell Mol Med; 2018 Sep; 22(9):4068-4075. PubMed ID: 29971911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. lncRNA NEAT1 promotes the Taxol resistance of breast cancer via sponging the miR-23a-3p-FOXA1 axis.
    Zhu L; Wang F; Fan W; Jin Z; Teng C; Zhang J
    Acta Biochim Biophys Sin (Shanghai); 2021 Aug; 53(9):1198-1206. PubMed ID: 34327529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.